annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Breast Cancer—Metastatic
Brd. 23A A randomized open-label, phase II study of lapatinib/capecitabine,
lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2amplified
metastatic breast cancer (MBC) progressing after taxane treatment-
GLICO-0801. (Abstract #TPS120)
H. L. Gomez, S. P. Neciosup, Y. Neron do Nascimento, G. Ismael, C. H. Barrios
Brd. 23B Suppression of bone turnover following treatment with zoledronic acid in
patients wtih metastatic breast cancer: Duration of effect—The SuBDuE
study. (Abstract #TPS121)
C. E. Simmons, E. Amir, E. Lee, S. Hogeveen, R. A. Dent, P. J. Goodwin, M.
Clemons
Brd. 23C Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib
(TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic
breast cancer. (Abstract #TPS122)
F. Andre, J. Baselga, M. J. Ellis, S. A. Hurvitz, H. S. Rugo, N. C. Turner, E.
Argonza-Aviles, S. Lake, M. M. Shi, O. Anak
Brd. 23D Multicentric, open-label, single-arm phase II study with oral lapatinib in
combination with oral capecitabine plus intrathecally administered liposomal
cytarabine for the treatment of meningeal metastases (NM) in HER2-positive
breast cancer patients. (Abstract #TPS123)
J. Bischoff
Brd. 23E Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w)
paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC).
(Abstract #TPS124)
P. G. Morris, J. C. Chang, A. Abbruzzi, S. Patil, S. Modi, A. D. Seidman, N. T.
Sklarin, L. Norton, C. Hudis, M. N. Fornier
Brd. 23F Clinical relevance of HER2 expression/activation, as measured in circulating
tumor cells by a multiplexed immunoassay, in women with HER2-negative
(by FISH) metastatic breast cancer (MBC). (Abstract #TPS125)
J. D. Hainsworth, D. A. Yardley, H. A. Burris
Brd. 23G Metronomic chemotherapy with cyclophosphamide and celecoxib in breast
cancer patients progressing after standard chemotherapy: Phase I/II trial.
(Abstract #TPS126)
V. R. Rozados, A. Rossa, C. M. Alasino, H. A. Perroud, F. N. Queralt, S. M.
Pezzotto, O. G. Scharovsky
Brd. 23H Randomized phase II study of metronomic chemotherapy (MC) plus
aromatase inhibitor (AI) versus MC alone in postmenopausal hormone
receptor-positive, metastatic breast cancer (MBC), with correlative
circulating endothelial cell (CEC), circulating endothelial progenitor cell
(CEP), VEGF, and VEGFR levels. (Abstract #TPS127)
N. Wong, K. Hui, F. Sun, Y. Yap, R. C. Ng, J. W. Chia, L. Ngo, S. Lo
Brd. 24A A double-blind, randomized, placebo-controlled phase II study of the
steroidal aromatase inhibitor exemestane with and without the isoform
selective histone deacetylase inhibitor (HDACi) entinostat in metastatic
breast cancer (MBC). (Abstract #TPS128)
D. A. Yardley, R. Ismail-Khan, J. F. Eakle, K. Miller, D. Paul, V. F. Borges, T. L.
Helsten, J. F. Kroener, B. Melichar, K. H. Tkaczuk
Brd. 24B N0733: Phase II trial of capecitabine and lapatinib plus or minus
cixutumumab in HER2-positive breast cancer. (Abstract #TPS129)
P. Haluska, M. M. Reinholz, A. C. Dueck, H. M. Linden, W. L. Lingle, A. M. Bernath,
M. C. Arbushites, H. Youssoufian, H. X. Chen, E. A. Perez
Brd. 24C Gene signature-based patient selection for dasatinib therapy in metastatic
breast cancer (MBC). (Abstract #TPS130)
L. Pusztai, S. L. Moulder, J. K. Litton, V. Valero, N. T. Ueno, P. H. Morrow, K.
Dotter, D. Mattair, L. C. Strauss, W. F. Symmans
316